Plaisier A P, Alley E S, Boatin B A, Van Oortmarssen G J, Remme H, De Vlas S J, Bonneux L, Habbema J D
Department of Public Health, Faculty of Medicine, Erasmus University Rotterdam, Netherlands.
J Infect Dis. 1995 Jul;172(1):204-10. doi: 10.1093/infdis/172.1.204.
Ivermectin is an effective drug for the treatment of human onchocerciasis, a disease caused by the parasitic filarial nematode Onchocerca volvulus. When humans are treated, the microfilariae normally found in the skin are rapidly and very nearly completely eliminated. Nonetheless, after a delay, microfilariae gradually reappear in the skin. This study is concerned with the causes of this delay. Hypotheses are tested by comparing the results of model calculations with skin microfilaria counts collected from 114 patients during a trial of five annual treatments in the focus area of Asubende, Ghana. The results obtained strongly suggest that annual treatment with ivermectin causes an irreversible decline in microfilariae production of approximately 30%/treatment. This result has important implications for public health strategies designed to eliminate onchocerciasis as a significant health hazard.
伊维菌素是治疗人类盘尾丝虫病的有效药物，盘尾丝虫病是由寄生丝状线虫盘尾丝虫引起的一种疾病。对人类进行治疗时，通常存在于皮肤中的微丝蚴会迅速且几乎完全被清除。尽管如此，经过一段时间延迟后，微丝蚴会逐渐重新出现在皮肤中。本研究关注这种延迟的原因。通过将模型计算结果与在加纳阿苏本德重点地区进行的五次年度治疗试验期间从114名患者收集的皮肤微丝蚴计数进行比较，对假设进行了检验。所获得的结果强烈表明，每年使用伊维菌素进行治疗会导致微丝蚴产量不可逆地下降，每次治疗约下降30%。这一结果对于旨在消除盘尾丝虫病这一重大健康危害的公共卫生策略具有重要意义。
